RSS

everolimus

It has been announced by Eisai that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for the use of Kisplyx (lenvatinib) in combination with everolimus for the treatment of advanced renal cell carcinoma more

News

Lenvatinib, discovered and developed by Eisai, has been submitted for review by the European Medicines Agency (EMA) for use in combination with everolimus to treat people with metastatic kidney cancer more

News